ABRAXANE® Plus Gemcitabine Demonstrates Significant Survival Advantage in ... Financial Post ABRAXANE is also approved in the European Union/European Economic Area (EU/EEA), Canada, Russia, Australia, New Zealand, India, Japan, South Korea, Sri Lanka, Bhutan, Nepal, United Arab Emirates and China for the treatment of metastatic breast cancer ... |
